Gentian Diagnostics ASA terminates NT-proBNP assay development
Moss, 6 May 2026
Following a comprehensive review of performance data and market dynamics, Gentian Diagnostics ASA (“Gentian” or the “Company”) has decided to discontinue the development program for its heart failure biomarker NT-proBNP. This decision reflects disciplined portfolio prioritisation and enables reallocation of resources toward higher-return opportunities within the company’s expanding product pipeline.
Despite extensive re optimization efforts that improved assay imprecision and overall analytical chemistry performance, available data indicate that the assay is not expected to reliably meet the clinical decision cut-off for exclusion of non-acute heart failure. Achieving these requirements would likely necessitate a substantially extended development program with high technical risk. In addition, market assessments indicate limited commercial demand for an acute only NT proBNP assay as a standalone product in an increasingly competitive and saturated market.
After evaluating a range of strategic alternatives and considering the overall risk profile, development timelines, and opportunity cost, the Company has decided to terminate the NT proBNP assay development project. The project has been fully written off, and an impairment charge of NOK 30.2 million has been recognised in the Q1’26 accounts. The impairment does not impact the company’s cash position and should be seen in the context of active portfolio management and capital discipline.
The development work has generated valuable technical data and insights that will be retained to support future biomarker and assay platform development initiatives. Commenting on the decision, Matti Heinonen, CEO of Gentian Diagnostics ASA, said: “While this outcome is disappointing, it is a disciplined decision that allows us to reallocate resources toward accelerating execution of Gentian’s expanding product pipeline. This includes a combination of proprietary assay programs and partnered development projects with leading global IVD companies. We continue to strengthen the alignment between our R&D and Business Development activities, prioritising projects with clear market needs, defined routes to commercialisation, and strong partner interest.”
Gentian will continue to provide updates on pipeline development and strategic priorities through its regular financial reporting.
IR contact: Njaal Kind, CEO njaal.kind@gentian.no +47 919 06 525 (mobile)
About Gentian Diagnostics Gentian Diagnostics (OSE: GENT) develops and manufactures high-quality in vitro diagnostic reagents. Our mission is to improve diagnostic efficiency to support better treatment decisions. Gentian’s expertise and focus lie in immunoassays, specifically within infections, inflammation, kidney disease, and heart failure. By converting existing, clinically relevant biomarkers to the most efficient high throughput analysers, the company contributes to cost savings and helps protect lives. Gentian Diagnostics is headquartered in Moss, Norway, and serves the global human and veterinary diagnostics markets through sales and representative offices in Sweden, the USA, and China. For more information, please visit www.gentian.com.
This information is considered to be inside information pursuant to the EU Market Abuse Regulation (MAR) and is subject to the disclosure requirements pursuant to MAR article 17, Section 5-12 the Norwegian Securities Trading Act. This stock exchange announcement was published by Ole Sørlie, Business Controller and IR at Gentian Diagnostics ASA on the date and time provided.